The collaboration brings together BMS' deep scientific expertise and Anthropic's frontier AI to accelerate the discovery, development and delivery of transformational medicines

BMS will deploy Claude's agentic capabilities, moving beyond conversational AI, to connect its people, systems and institutional knowledge at enterprise scale

Bristol Myers Squibb (NYSE:BMY, ", BMS", ))), a global biopharmaceutical leader, today announced a strategic agreement with Anthropic to deploy Claude across the company's research, clinical development, manufacturing, commercial, and corporate functions. The collaboration signals a meaningful evolution in how BMS deploys AI, moving beyond conversational tools that have defined the first wave of enterprise adoption, toward agentic capabilities built into the day-to-day workflows and systems that underpin its science and global operations.

BMS will deploy Claude broadly across the company, empowering more than 30,000 employees with advanced reasoning and agentic capabilities. The deployment focuses on three priorities where BMS expects the highest near-term impact:

1. Accelerating engineering with Claude Code. BMS' engineering and data science teams will leverage Claude Code to speed software and AI development. By standardizing how they build and deploy capabilities across the enterprise, teams can unlock data and expertise long trapped in the disconnected systems that define biopharma today.
   
    
2. Embedding agents into the workflows that move drugs forward. BMS will evaluate the potential for Claude to serve as the agentic layer within priority workflows where AI is already driving impact across the value chain, including:
   • Research: Applying advanced AI reasoning to decades of BMS' proprietary scientific, molecular, and clinical data, further enabling researchers to synthesize, interrogate, and extract predictive insights that accelerate target identification and optimization across oncology, hematology, neuroscience, and immunology.
   • Drug development: Bringing intelligent automation to the full arc of trial documentation, from drafting clinical study reports and patient safety narratives to supporting regulatory submissions, with the potential to compress the time between data lock and filing.
   • Manufacturing & quality: Enabling end‑to‑end acceleration across product development and manufacturing, from root‑cause investigation and Corrective and Preventive Action documentation to data‑driven batch release decisions - strengthening quality and compliance, accelerating decision‑making, and delivering medicines to patients faster and more reliably.
   • Commercial & medical affairs: Turning field insights into structured intelligence that enables more personalized and timely engagement with healthcare professionals, helping BMS connect the right information to the right people at the moments that matter most in their practice.
     
      
3. Connecting Claude to the institutional knowledge that lives across BMS. Through secure integrations with the systems and repositories where BMS' scientific, clinical, regulatory, and commercial expertise resides, Claude's agentic capabilities will help connect and activate that knowledge where and when it is most needed, with full enterprise governance and audit controls in place.

The collaboration builds on more than three years of AI investment at BMS, where the company has given employees unlimited access to leading frontier models through a proprietary internal platform. Those investments have established BMS as a leader in AI integration across research, clinical development, manufacturing and commercial functions, and reflect a deliberate multi-vendor strategy that draws on the best capabilities the industry has to offer.